West Nile virus central nervous system infection in patients treated with rituximab: Implications for diagnosis and prognosis, with a review of literature

Open Forum Infectious Diseases

Volumn 2, Issue 4, 2015, Pages

  Morjaria, Sejal ^a   Arguello, Esther ^a   Taur, Ying ^a   Sepkowitz, Kent ^a   Hatzoglou, Vaios ^a   Nemade, Ajay ^a   Rosenblum, Marc ^a   Cavalcanti, Marcela S ^a   Lia Palomba, M ^a   Kaltsas, Anna ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Immunocompromised host; Lymphoma; Molecular testing; Rituximab; West Nile virus

Indexed keywords

ACICLOVIR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; CANCER STAGING; CASE REPORT; CELLULITIS; CENTRAL NERVOUS SYSTEM INFECTION; ENCEPHALITIS; EYE PAIN; FEBRILE NEUTROPENIA; FEVER; HALLUCINATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LARGE CELL LYMPHOMA; LUMBAR PUNCTURE; MALE; MENINGITIS; MOSQUITO BITE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLURRED SPEECH; TINEA VERSICOLOR; WEST NILE VIRUS;

EID: 85014199950     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv136     Document Type: Article

References (11)

1. Winston DJ, Vikram HR, Rabe IB, et al. Donor-derivedWest Nile virus infection in solid organ transplant recipients: report of four additional cases and review of clinical, diagnostic, and therapeutic features. Transplantation 2014; 97:881-9.
2. Huang C, Slater B, Rudd R, et al. First isolation ofWest Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis 2002; 8:1367-71.
3. Levi ME, Quan D, Ho JT, et al. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin Transplant 2010; 24:223-8.
4. Mawhorter SD, Sierk A, Staugaitis SM, et al. Fatal West Nile virus infection after rituximab/fludarabine-induced remission for non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2005; 6:248-50.
5. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187-98.
6. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48:1307-12.
7. Samuel MA, Diamond MS. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 2006; 80:9349-60.
8. Diamond MS, Sitati EM, Friend LD, et al. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 2003; 198:1853-62.
9. Diamond MS, Shrestha B, Marri A, et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 2003; 77:2578-86.
10. Centers for Disease Control and Prevention. West Nile Virus. Available at: http://www.cdc.gov/ncidod/dvbid/westnile/surv@control.htm. Accessed 18 December 2014.
11. Martin DA, Muth DA, Brown T, et al. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. J Clin Microbiol 2000; 38:1823-6.